Last reviewed · How we verify
Anti-RANKL Monoclonal Antibody
Anti-RANKL Monoclonal Antibody is a Monoclonal antibody Biologic drug developed by Shanghai JMT-Bio Inc.. It is currently in Phase 1 development for Osteoporosis. Also known as: JMT103.
Inhibits RANKL
Inhibits RANKL Used for Osteoporosis.
At a glance
| Generic name | Anti-RANKL Monoclonal Antibody |
|---|---|
| Also known as | JMT103 |
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | Monoclonal antibody |
| Target | RANKL |
| Modality | Biologic |
| Therapeutic area | Osteoporosis |
| Phase | Phase 1 |
Mechanism of action
RANKL inhibition prevents osteoclast formation and bone resorption.
Approved indications
- Osteoporosis
Common side effects
- Hypersensitivity
- Infection
- Infusion-related reaction
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-RANKL Monoclonal Antibody CI brief — competitive landscape report
- Anti-RANKL Monoclonal Antibody updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI
Frequently asked questions about Anti-RANKL Monoclonal Antibody
What is Anti-RANKL Monoclonal Antibody?
Anti-RANKL Monoclonal Antibody is a Monoclonal antibody drug developed by Shanghai JMT-Bio Inc., indicated for Osteoporosis.
How does Anti-RANKL Monoclonal Antibody work?
Inhibits RANKL
What is Anti-RANKL Monoclonal Antibody used for?
Anti-RANKL Monoclonal Antibody is indicated for Osteoporosis.
Who makes Anti-RANKL Monoclonal Antibody?
Anti-RANKL Monoclonal Antibody is developed by Shanghai JMT-Bio Inc. (see full Shanghai JMT-Bio Inc. pipeline at /company/shanghai-jmt-bio-inc).
Is Anti-RANKL Monoclonal Antibody also known as anything else?
Anti-RANKL Monoclonal Antibody is also known as JMT103.
What drug class is Anti-RANKL Monoclonal Antibody in?
Anti-RANKL Monoclonal Antibody belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.
What development phase is Anti-RANKL Monoclonal Antibody in?
Anti-RANKL Monoclonal Antibody is in Phase 1.
What are the side effects of Anti-RANKL Monoclonal Antibody?
Common side effects of Anti-RANKL Monoclonal Antibody include Hypersensitivity, Infection, Infusion-related reaction.
What does Anti-RANKL Monoclonal Antibody target?
Anti-RANKL Monoclonal Antibody targets RANKL and is a Monoclonal antibody.
Related
- Drug class: All Monoclonal antibody drugs
- Target: All drugs targeting RANKL
- Manufacturer: Shanghai JMT-Bio Inc. — full pipeline
- Therapeutic area: All drugs in Osteoporosis
- Indication: Drugs for Osteoporosis
- Also known as: JMT103
- Compare: Anti-RANKL Monoclonal Antibody vs similar drugs
- Pricing: Anti-RANKL Monoclonal Antibody cost, discount & access